Information procedures, review times and web sites aired at recent update meeting in Washington
This article was originally published in Clinica
The FDA is looking at how to interpret a clause in the FDA Modernisation Act, intended to keep overzealous product reviewers in check. However, it is not clear whether or not the agency will produce an actual guidance document on the subject, Susan Alpert, director of the Office of Device Evaluation said last week.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
HBW Market News: FTC Ends Another Supplement Scam, Australia Win For ChromaDex, GOED Report, Herbalife
Herbalife opens 9,200 square-foot training facility in China; GOED's latest annual market report, covering 2017-2018, is available; ChromaDex has two-tear exclusivity for nicotinamide riboside chloride in Australia; and A.S. Research arthritis claims for Synovia end in FTC settlement.
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.